Murray Stewart
Directeur/Membre du Conseil chez X4 PHARMACEUTICALS, INC.
Fortune : 193 419 $ au 31/05/2024
Postes actifs de Murray Stewart
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| X4 PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 29/03/2019 | - |
| Directeur Technique/Scientifique/R&D | 29/11/2022 | 01/08/2023 | |
| Vivli Center For Global Clinical Research Data | Directeur/Membre du Conseil | - | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Murray Stewart
Anciens postes connus de Murray Stewart
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VECTIVBIO HOLDING AG | Directeur/Membre du Conseil | 02/09/2021 | 26/06/2023 |
| Independent Dir/Board Member | 02/09/2021 | 26/06/2023 | |
| AMARIN CORPORATION PLC | Directeur/Membre du Conseil | 10/01/2023 | 06/03/2023 |
| Independent Dir/Board Member | 10/01/2023 | 06/03/2023 | |
| RHYTHM PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 15/10/2018 | 10/09/2021 |
| NOVELION THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 27/11/2017 | 17/10/2018 |
| GSK PLC | Directeur Technique/Scientifique/R&D | 01/04/2014 | 01/11/2017 |
| Corporate Officer/Principal | - | - |
Formation de Murray Stewart
| The University of Southampton | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Royaume-Uni | 3 |
| Suisse | 3 |
Opérationnelle
| Director/Board Member | 5 |
| Chief Tech/Sci/R&D Officer | 4 |
| Independent Dir/Board Member | 2 |
Sectorielle
| Health Technology | 8 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GSK PLC | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| AMARIN CORPORATION PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| Vivli Center For Global Clinical Research Data | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Bourse
- Insiders
- Murray Stewart
- Expérience
